FGFR1 and melanoma: Most notably, 1,25(OH)2D3 sensitised A375 melanoma cells to the novel FGFRs inhibitor, CPL304110, at the posttranscriptional level, decreasing the FGFR1 and 2 protein level as well as their activation.